Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild‐type glioblastoma patients

2 Mar 2016

Abstract excerpt

MGMT promoter methylation status is currently the only established molecular prognosticator in IDH wild-type glioblastoma multiforme (GBM). Therefore, we aimed to discover novel therapy-associated epigenetic biomarkers. After enrichment for hypermethylated fractions using methyl-CpG-immunoprecipitation (MCIp), we performed global DNA methylation profiling for 14 long-term (LTS; >36 months) and 15 short-term (STS;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26934681
DOI: 10.1002/ijc.30069

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild‐type glioblastoma patientsPMID 26934681Read ↗

DNA methylation profiles of long- and short-term glioblastoma survivors.Semantic proximity Read ↗

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.Semantic proximity Read ↗

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.Semantic proximity Read ↗

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.Semantic proximity Read ↗

Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.Semantic proximity Read ↗

Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.Semantic proximity Read ↗

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.Semantic proximity Read ↗

Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.Semantic proximity Read ↗

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.Semantic proximity Read ↗

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.Semantic proximity Read ↗

Mean global DNA methylation serves as independent prognostic marker in IDH-wildtype glioblastomaSemantic proximity Read ↗

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.